

Accepted Manuscript

Predicting histological subtypes of Follicular Variant of Papillary Thyroid Carcinoma based on cytomorphology. Can cytomorphology optimize use of molecular testing?

Ryan Glass, Leonard Kahn, Momin T. Siddiqui, Rubina Cocker



PII: S2213-2945(16)30011-4

DOI: [10.1016/j.jasc.2016.04.002](https://doi.org/10.1016/j.jasc.2016.04.002)

Reference: JASC 192

To appear in: *Journal of the American Society of Cytopathology*

Received Date: 4 March 2016

Revised Date: 5 April 2016

Accepted Date: 6 April 2016

Please cite this article as: Glass R, Kahn L, Siddiqui MT, Cocker R, Predicting histological subtypes of Follicular Variant of Papillary Thyroid Carcinoma based on cytomorphology. Can cytomorphology optimize use of molecular testing?, *Journal of the American Society of Cytopathology* (2016), doi: 10.1016/j.jasc.2016.04.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Title: Predicting histological subtypes of Follicular Variant of Papillary Thyroid Carcinoma based on cytomorphology. Can cytomorphology optimize use of molecular testing?

Author Names: Ryan Glass¹, Leonard Kahn¹, Momin T. Siddiqui², Rubina Cocker¹

Author Affiliations: 1-Northwell Health, Department of Pathology. Lake Success, NY.2-Emory University Hospital, Department of Pathology. Atlanta, GA

Running Title: Cytology Predicting FVPTC Subtypes

Corresponding Author Information: Rubina Cocker. Northwell Health, Department of Pathology. 6 Ohio Drive. Lake Success, NY 11042. Email: Rcocker@northwell.edu

Abstract:

Background: Follicular Variant Papillary Thyroid Carcinoma (FVPTC) can be further subclassified into one of three subtypes: Non-invasive encapsulated FVPTC, Invasive encapsulated FVPTC, and Infiltrative FVPTC. Longitudinal and molecular studies have demonstrated that, in terms of both molecular profiles and prognosis, encapsulated FVPTC is comparable to follicular adenoma, invasive FVPTC to follicular carcinoma, and infiltrative FVPTC to classic PTC. To improve triaging and prevent overtreatment of patients with FVPTC, we sought to determine cytologic features likely to occur within each subtype.

Methods: A laboratory database search from 2010-2015 was conducted to identify patients with biopsy-proven FVPTC and prior fine needle aspiration. Surgical specimens were reviewed to determine the appropriate subcategorization. Accompanying cytology reports were reviewed for features common in classic PTC and follicular neoplasms. **Results:** Encapsulated variants were more likely to be graded as Bethesda Category 4 compared to invasive or infiltrative variants. In contrast, Infiltrative variants were more likely to be graded as Bethesda Categories 5 and 6 compared to invasive or encapsulated variants. Compared to the encapsulated variant, infiltrative FVPTC was more likely to have nuclear pseudo-inclusions (31.82% vs 8.11%, $p=0.0468$) and less likely to have microfollicular architecture (22.73% vs 54.05%, $p=0.0374$). **Conclusions:** This study identified Cytomorphological differences between encapsulated and infiltrative FVPTC. With a higher threshold of suspicion for FVPTC, improved awareness of the differences between these subtypes and incorporation of molecular testing, it is likely that the Bethesda Category can be revised and patient triaging can be significantly improved.

Key Words: NIFT, Follicular Variant, Papillary Thyroid Carcinoma, Non-Invasive, Cytology, BRAF, RET, RAS

Download English Version:

<https://daneshyari.com/en/article/5584638>

Download Persian Version:

<https://daneshyari.com/article/5584638>

[Daneshyari.com](https://daneshyari.com)